NEW YORK (GenomeWeb) – Qiagen has entered into a collaboration and comarketing agreement with Centogene, a German firm focusing on genetic diagnosis of rare disease, in an attempt to integrate sample-to-insight research with clinical testing for rare conditions.

The centerpiece of the agreement is the integration of Centogene's CentoMD database of 4.5 million clinically annotated phenotype and genotype variants of rare diseases into the Qiagen Clinical Insight bioinformatics platform and companion knowledge base.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The UK's Human Fertility and Embryology Authority calls for consumer genetic testing companies to warn customers that testing could uncover family secrets, according to the Guardian.

The New York Times reports that United Nations delegates have been discussing how to govern the genetic resources of the deep sea.

Researchers have transplanted edited cells into mice that appear to combat cocaine addiction, New Scientist reports.

In PNAS this week: analysis of proteolytic enzymes secreted by circulating tumor cells, phylogenetic study of Fv1 evolution, and more.